Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Trine Trab, Iman Chanchiri, Ahmed Al-Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Simon Husby, Michael Roost Clausen, Thomas Stauffer Larsen, Andriette C Desseau-Arp, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Peter de Nully Brown, Tarec Christoffer El-Galaly, Kirsten Gronbaek

Blood (2024) 144 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2024-201293

Published: 2024

Journal Articles

Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study

Sara Harrysson, Sandra Eloranta, Stefanie Antonilli, Mikkel Runason Simonsen, Kristina Sonnevi, Peter de Nully Brown, Bjorn E Wahlin, P-O Andersson, Judit Mészáros Joergensen, Mats Jerkeman, Christian Bjørn Poulsen, Gunilla Enblad, Tarec Christoffer El-Galaly, Karin Ekstroem Smedby

Blood (2024) 144 (Supplement 1): 654.

https://doi.org/10.1182/blood-2024-201964

Published: 2024

Journal Articles

Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022

Peter Brændstrup, Thomas Bech Mortensen, Tarec Christoffer El-Galaly, Michael Boe Møller, Judit Mészáros Joergensen, Christian Bjørn Poulsen, Peter de Nully Brown, Dennis Lund Hansen, Thomas Stauffer Larsen

Blood (2024) 144 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2024-199691

Published: 2024

Journal Articles

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Sara Rossetti, Sidsel Jacobsen Juul, Frank Eriksson, Peder Emil Warming, Charlotte Glinge, Tarec Christoffer Christoffer El-Galaly, Jacob Haaber Christensen, Peter Kamper, Peter de Nully Brown, Maja Maraldo, Jacob Tfelt-Hansen, Martin Hutchings

Blood (2023) 142 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2023-172989

Published: 2023

Journal Articles

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Leo Meriranta, Maare Arffman, Judit Mészáros Jørgensen, Harald Holte, Kristina Drott, Henrikki Almusa, Emma Saarinen, Sari Hannula, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Ølgod Pedersen, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2023-188493

Published: 2023

Journal Articles

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Blood (2023) 142 (Supplement 1): 295.

https://doi.org/10.1182/blood-2023-173957

Published: 2023

Journal Articles

A Population-Based Study on Performance of Clinical Prognostic Models in Patients with Diffuse Large B-Cell Lymphoma Younger Than 70 Years

Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Peter de Nully Brown, Tarec Christoffer Christoffer El-Galaly, Thomas Stauffer Larsen

Blood (2023) 142 (Supplement 1): 190.

https://doi.org/10.1182/blood-2023-182606

Published: 2023

Journal Articles

Polypharmacy Independently Predicts Overall Survival in Patients with Lymphoid Cancer

Christian Brieghel, Emelie Curovic Rotbain, Michael Asger Andersen, Peter de Nully Brown, Carsten Utoft Niemann

Blood (2023) 142 (Supplement 1): 5133.

https://doi.org/10.1182/blood-2023-187262

Published: 2023

Journal Articles

Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas

Maare Arffman, Leo Meriranta, Judit Mészáros Jørgensen, Harald Holte, Øystein Fluge, Peter de Nully Brown, Kristina Drott, Sirkku Jyrkkiö, Suvi-Katri Leivonen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2023-177849

Published: 2023

Journal Articles

Impact of Trial Eligibility Criteria on Outcomes of 1,245 Patients with Follicular Lymphoma Treated in the Real-World Setting: A Danish Population-Based Study

Tine Bennedsen, Mikkel Simonsen, Peter de Nully Brown, Michael Roost Clausen, Andriette Dessau-Arp, Judit Jørgensen, Thomas S. Larsen, Christian Bjørn Poulsen, Lasse Hjort Jakobsen, Tarec Christoffer Christoffer El-Galaly

Blood (2022) 140 (Supplement 1): 3612–3614.

https://doi.org/10.1182/blood-2022-156376

Published: 2022

Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 2292–2295.

https://doi.org/10.1182/blood-2022-157194

Published: 2022

Journal Articles

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Blood (2022) 140 (Supplement 1): 1768–1769.

https://doi.org/10.1182/blood-2022-158183

Published: 2022

Journal Articles

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1921–1923.

https://doi.org/10.1182/blood-2022-164692

Published: 2022

Journal Articles

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Blood (2022) 140 (Supplement 1): 1479–1480.

https://doi.org/10.1182/blood-2022-158981

Published: 2022

Journal Articles

Outcome after 3 rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Blood (2022) 140 (Supplement 1): 6706–6707.

https://doi.org/10.1182/blood-2022-167897

Published: 2022

Journal Articles

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Maare Arffman, Leo Meriranta, Harald Holte, Judit Jørgensen, Peter De Nully Brown, Sirkku Jyrkkio, Mats Jerkeman, Øystein Fluge, Magnus Björkholm, Matias Autio, Suvi-Katri Leivonen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 1316–1317.

https://doi.org/10.1182/blood-2022-158426

Published: 2022

Journal Articles

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Simon Husby, Gustav Ørting Jørgensen, Francesco Favero, Jakob Schmidt Jespersen, German G.R. Gonzalez, Christian Nielsen, Betina Sørensen, Lene Hyldahl Ebbesen, John Bæch, Eva Kannik Hastrup, Pär L. Josefsson, Michael Thorsgaard, Tarec Christoffer El-Galaly, Peter de Nully Brown, Thomas Stauffer Larsen, Joachim Weisenfeldt, Kirsten Grønbæk

Blood (2021) 138 (Supplement 1): 3942.

https://doi.org/10.1182/blood-2021-145417

Published: 2021

Journal Articles

Mental Health Among Patients with Non-Hodgkin Lymphoma: A Danish Nationwide Study of Psychotropic Drug Use in 7,201 Patients and 36,005 Matched Comparators

Andreas Kiesbye Øvlisen, Lasse H. Jakobsen, Kristian Hay Kragholm, René Ernst Nielsen, Peter De Nully Brown, Rasmus Bo Dahl-Soerensen, Henrik Frederiksen, Nikolaj Mannering, Pär L. Josefsson, Ahmed Al-Mashhadi, Judit M. Jørgensen, Andriette Dessau-Arp, Michael Roost Clausen, Robert Schou Pedersen, Christian Torp-Pedersen, Marianne Tang Severinsen, Tarec Christoffer El-Galaly

Blood (2021) 138 (Supplement 1): 51.

https://doi.org/10.1182/blood-2021-150163

Published: 2021

Journal Articles

The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP

Freja Tang Severinsen, Laura Mors Haunstrup, Rasmus Kuhr Jensen, Matthew J. Maurer, Arushi Khurana, Paw Jensen, Judit M. Jørgensen, Thomas Stauffer Larsen, Michael Roost Clausen, Christian Bjørn Poulsen, Peter de Nully Brown, Tarec Christoffer El-Galaly, Lasse H. Jakobsen

Blood (2021) 138 (Supplement 1): 53.

https://doi.org/10.1182/blood-2021-151100

Published: 2021

Journal Articles

Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study

Joachim Baech, Marianne Tang Severinsen, Andreas Kiesbye Øvlisen, Henrik Frederiksen, Peter Vestergaard, Christian Torp-Pedersen, Judit M. Jørgensen, Michael Roost Clausen, Christian Bjørn Poulsen, Peter de Nully Brown, Anne Ortved Gang, Robert Schou Pedersen, Karin Ekstroem Smedby, Sandra Eloranta, Lasse H. Jakobsen, Tarec Christoffer El-Galaly

Blood (2021) 138 (Supplement 1): 454.

https://doi.org/10.1182/blood-2021-144733

Published: 2021

NARROW

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study

Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

A Population-Based Study on Performance of Clinical Prognostic Models in Patients with Diffuse Large B-Cell Lymphoma Younger Than 70 Years

Polypharmacy Independently Predicts Overall Survival in Patients with Lymphoid Cancer

Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas

Impact of Trial Eligibility Criteria on Outcomes of 1,245 Patients with Follicular Lymphoma Treated in the Real-World Setting: A Danish Population-Based Study

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Outcome after 3 rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Mental Health Among Patients with Non-Hodgkin Lymphoma: A Danish Nationwide Study of Psychotropic Drug Use in 7,201 Patients and 36,005 Matched Comparators

The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP

Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only